Medicare Part D Spending in 2019 Lower Than Expected Because Of Rebates
Medicare Trustees Report highlights importance of rebates in Part D but does not address potential changes to system; charts detail the growing impact rebates are expected to have in coming years.
You may also be interested in...
Manufacturers, pharmacy benefit managers and insurers weigh in on the Trump administration’s most significant drug pricing action to date – the HHS Office of Inspector General's proposed rule aimed at eliminating rebates.
HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.
Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.